top of page

Come Join Me

I will be leading a forum about "More nuanced clinical outcomes from person-generated health data" at DIA's Global Annual Meeting in San Diego on June 20.     Should be really interesting!

N DREYER 0021 WEB_edited.jpg

Pragmatic leader experienced in using real-world evidence to improve health

Nancy A. Dreyer, MPH, PhD, FISPE

Seasoned  Business Leader/ Serial Entrepreneur/ Expert in Real-World Evidence

Nancy Dreyer is Adjunct Professor of Epidemiology at the University of North Carolina at Chapel Hill, Chief Scientific Advisor to Picnic Health and a Trustee of Brandeis University.  Recently retired from full-time employment as the Chief Scientific Officer for IQVIA Real World Solutions, she is well-known for her thought leadership and a popular public speaker. She has helped advance the use of real-world evidence for clinical decision support and regulatory purposes, influencing the content of guidelines by regulators in the US, Europe, and China, each of which cite one or more of her publications.  Her experience includes biopharmaceutical, occupational and environmental research. 

Her substantial executive and field experience have helped hone her pragmatic views.

Profile overview

Areas of expertise

Education & Fellowships

Recent External highlights

35+ years of experience in epidemiology and business including

  • IQVIA SVP and Chief Scientific Officer

  • Quintiles/Outcome Sciences Inc, SVP, Chief of Scientific Affairs

  • i3 Research/Ingenix, UnitedHealth Group, SVP

  • Epidemiology Resources, Inc. and the New England Epidemiology Institute, CEO & Chair of the Board

  • Developing reliable real-world evidence (RWE), including person-generated health data

  • Regulatory use of RWE for market authorization and label expansion

  • Assessing the relevance and reliability of RWE for decision support 

  • Health data linkage

  • BA, Brandeis University

  • Master of Public Health, Epidemiology, University of North Carolina

  • PhD, Epidemiology, University of North Carolina

  • Fellow, International Society of Pharmacoepidemiology & the Drug Information Association

  • Chief Scientific Advisor, Picnic Health

  • Adjunct Professor of Epidemiology, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC

  • Drug Information Association Scientific & Policy Advisory Council and former Director

  • Duke-Margolis Center for Health Policy Research Planning Board

  • Brandeis University, Trustee 

Selected Recent Publications

  • Dreyer NA and Blackburn SCF.  Power to the people: Why person-generated health data is important for pharmacoepidemiology.  American Journal of Epidemiology 2024: 

  • Dreyer NA et al. COVID-19 vaccination reactions and risk of breakthrough infections among people with diabetes: cohort study derived from community reporters. JMIR Diabetes 2024; e45536,  doi: 10.2196/45536

  • Dreyer NA, Mack CD.  Tactical considerations for designing real-world studies: Fit-for-purpose designs that bridge research and practice.  Pragmatic and Observational Research 2023:14 101–110  

  • Brinkley E... Dreyer N.  Daily COVID-19 symptom assessment over 28 days–findings from a daily direct-to-patient registry of COVID-19 positive patients.  Journal of Patient-‌Reported Outcomes 2023; 7 (1):1-‌5

  • Largent JA, Xie X...and Dreyer NA. Cognitive and other neuropsychiatric symptoms in COVID-19: Analysis of person-generated longitudinal health data from a community-based registry, BMJ Open 2023 ;13:e069118. doi:10.1136/ bmjopen-2022-069118

  • Dreyer NA.  Strengthening evidence-based medicine with real-world evidence.  Invited Commentary.  Lancet Healthy Longevity 2022 Oct;3(10):e641-e642. doi: 10.1016/S2666-7568(22)00214-8. Epub 2022 Sep 20. PMID: 36150401.

  • Dreyer NA, Reynolds MW, Albert L, Brinkley E, Kwon T, Mack C, Toovey S.  How frequent are acute reactions to COVID-19 vaccination and who is at risk?  Vaccine 2022; 40 (12): 1904-1912.  

  • Sridhara R, Marchenko O, Jiang Q, Barkdsale E. Chen J, Dreyer N et al. Evaluation of treatment effects in underrepresented populations in cancer trials: Discussion with international regulators.  Statistics in Biopharmaceutical Research 2022:1-7 

bottom of page